These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 30270089)

  • 1. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
    Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Vohnout B; Fábryová Ľ; Klabník A; Kadurová M; Bálinth K; Kozárová M; Bugáňová I; Sirotiaková J; Rašlová K
    Atherosclerosis; 2018 Oct; 277():323-326. PubMed ID: 30270066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
    Alonso R; Arroyo-Olivares R; Díaz-Díaz JL; Fuentes-Jiménez F; Arrieta F; de Andrés R; Gonzalez-Bustos P; Argueso R; Martin-Ordiales M; Martinez-Faedo C; Illán F; Saenz P; Donate JM; Sanchez Muñoz-Torrero JF; Martinez-Hervas S; Mata P
    Atherosclerosis; 2024 Jun; 393():117516. PubMed ID: 38523000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.
    Baum SJ; Brown AS
    Rev Cardiovasc Med; 2018; 19(S1):S25-S30. PubMed ID: 30207555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS; Kiouri E; Katsimardos A; Kotakos C
    Atherosclerosis; 2018 Aug; 275():262-264. PubMed ID: 29980053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Brunham LR; Ruel I; Khoury E; Hegele RA; Couture P; Bergeron J; Baass A; Dufour R; Francis GA; Cermakova L; Mancini GBJ; Brophy JM; Brisson D; Gaudet D; Genest J
    Atherosclerosis; 2018 Oct; 277():419-424. PubMed ID: 30270080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL; Pirillo A; Norata GD
    Vasc Health Risk Manag; 2017; 13():343-351. PubMed ID: 28919772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.